"As Jazz Pharmaceuticals plc, we are a growing, profitable specialty biopharmaceutical company with a diverse portfolio of products in the central nervous system and women's health areas," said Bruce Cozadd, chairman and CEO at Jazz Pharmaceuticals. "We now have a strengthened management team, a broader commercial organization and an efficient platform for further growth, with resources to build our product portfolio and a future pipeline."
Jazz Pharmaceuticals has approximately 430 employees, including a commercial organization focused around four key areas: narcolepsy, severe chronic pain, psychiatry and a diversified portfolio of women's health products. In addition to its headquarters in Dublin, Ireland, the company has offices in Palo Alto, Calif., and Philadelphia, Penn.
